Alaric DeArment
Reporter
Latest From Alaric DeArment
Proteome-Focused ProFound Emerges From Flagship Pioneering
The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.
Could CAR-Ts Roll Into The Community Setting?
While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space.
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
Ocuphire Chalks Up Another Phase III Success For Nyxol
The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.
Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'
The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.